Adial Pharma Files 8-K: Administrative Update, No New Financials

TL;DR

**Adial Pharma's 8-K is just an admin update, nothing to trade on.**

AI Summary

Adial Pharmaceuticals, Inc. filed an 8-K on January 16, 2024, reporting an event from January 11, 2024. This filing primarily updates administrative information, including their business address at 1180 Seminole Trail, Suite 495, Charlottesville, Virginia 22901, and confirms their status as a Delaware corporation. For investors, this filing is largely administrative and does not contain new financial or operational news that would directly impact the stock price, but it confirms the company's current official details.

Why It Matters

This filing is mainly administrative, updating contact and corporate information. It doesn't contain new financial results or strategic announcements that would immediately move the stock.

Risk Assessment

Risk Level: low — This filing contains only administrative updates and does not introduce new financial risks or opportunities.

Analyst Insight

Investors should note this filing is purely administrative and does not contain new material information that would warrant immediate trading action. It's a routine update.

Key Players & Entities

• ADIAL PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Adial Pharmaceuticals, Inc.
• 1180 Seminole Trail, Suite 495, Charlottesville, Virginia 22901 (dollar_amount) — business address of Adial Pharmaceuticals, Inc.
• January 11, 2024 (dollar_amount) — date of the earliest event reported in the 8-K
• January 16, 2024 (dollar_amount) — date the 8-K was filed

FAQ

Filing Documents

• ea191680-8k_adialpharma.htm (8-K) — 36KB
• 0001213900-24-003750.txt ( ) — 248KB
• adil-20240111.xsd (EX-101.SCH) — 3KB
• adil-20240111_def.xml (EX-101.DEF) — 26KB
• adil-20240111_lab.xml (EX-101.LAB) — 36KB
• adil-20240111_pre.xml (EX-101.PRE) — 25KB
• ea191680-8k_adialpharma_htm.xml (XML) — 5KB

07. Submission

Item 5.07. Submission of Matters to a Vote of Security Holders. On January 11, 2024, Adial Pharmaceuticals, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") at which the Company's stockholders voted on two (2) proposals (the "Proposals") and cast their votes as described below. These Proposals are described in detail in the Company's definitive proxy statement on Schedule 14A for the Special Meeting that was initially filed with the Securities and Exchange Commission ("SEC") on December 8, 2023, as supplemented by the filing with the SEC of definitive additional materials on December 15, 2023 (the "Definitive Proxy Statement"). At the Special Meeting, the Company's stockholders were asked to vote on the following two (2) Proposals: Proposal 1 : Approval of, pursuant to Nasdaq listing rules, of the issuance of up to an aggregate of 3,007,092 shares of the Company's common stock upon the exercise of common stock purchase warrants issued or issuable to an institutional investor and designees of the placement agent in connection with the Company's private placement offering that closed on October 24, 2023 that may be equal to or exceed 20% of the Company's common stock outstanding before such offering. This proposal is referred to as the "Warrant Exercise Proposal" or "Proposal 1." The stockholders approved Proposal 1 based on the votes listed below: Votes For Votes Against Abstentions Broker Non-Votes 432,915 51,550 6,621 0 Proposal 2 : Approval of an adjournment of the Special Meeting to a later date, if necessary, to permit furth solicitation and vote of proxies in the event there are not sufficient votes in favor of the Warrant Exercise Proposal. This proposal is referred to as the "Adjournment Proposal" or "Proposal 2." The Adjournment Proposal was presented at the Special Meeting but not needed as Proposal 1 received a sufficient number of votes for approval. The stockholders approved Proposal 2 based on the vote

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 16, 2024 ADIAL PHARMACEUTICALS, INC. By: /s/ Cary J. Claiborne Name: Cary J. Claiborne Title: President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR